 |
|
 2007 NEWS ARCHIVE |
| |
| METABOLEX BEGINS PHASE 2 TRIAL OF MBX-8025 FOR TREATMENT OF DYSLIPIDEMIA |
|
| September 25, 2007 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides to assess the drug’s effect on dyslipidemia, insulin-resistance and obesity ... |
| |
|
More > |
| |
| METABOLEX ANNOUNCES ASTELLAS HAS BEGUN HIGH-THROUGHPUT SCREENING ON UNIQUE TARGET FROM METABOLEX GENE DATABASE |
|
| September 19, 2007 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that Astellas Pharma Inc. has begun high-throughput screening against an additional target from Metabolex’s proprietary human gene database. Astellas is working to identify potential drug candidates by examining genes associated with insulin resistance and obesity ... |
| |
|
More > |
| |
| METABOLEX APPOINTS MCWHERTER SENIOR VICE PRESIDENT
FOR RESEARCH AND PRECLINICAL DEVELOPMENT |
|
| August 2, 2007 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has hired Charles A. McWherter, Ph.D., as senior vice president, research and preclinical development. Dr. McWherter, who will be responsible for the discovery and development of the company’s preclinical drug candidates, joins the company from Pfizer, Inc. where he served as vice president and head of the cardiovascular therapeutic area ... |
| |
|
More > |
| |
| METABOLEX ANNOUNCES FULL ENROLLMENT OF PHASE 2/3 STUDY OF
MBX-102/JNJ 39659100 IN PATIENTS WITH TYPE 2 DIABETES |
|
| July 19, 2007 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced that it has completed enrollment in the 400-patient Phase 2/3 study of its novel insulin sensitizer, MBX-102/JNJ 39659100, in patients with type 2 diabetes. Metabolex will receive a milestone ... |
| |
|
More > |
| |
| METABOLEX ANNOUNCES ELECTION OF ROBERT B. CHESS TO BOARD OF DIRECTORS |
|
| June 26, 2007 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced that Robert B. Chess has been elected to its Board of Directors ... |
| |
|
More > |
| |
| METABOLEX NAMES CHARPENTIER TO THE POST OF VICE PRESIDENT FOR REGULATORY AFFAIRS |
|
| May 3, 2007 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has hired Bonnie Charpentier as vice president, regulatory affairs. In that position, Charpentier will oversee all aspects of regulatory compliance ... |
| |
|
More > |
| |
| METABOLEX RAISES $32 MILLION TO ACCELERATE CLINICAL DEVELOPMENT PROGRAMS FOR ITS PIPELINE OF DRUG CANDIDATES IN METABOLIC DISEASE |
|
| April 19, 2007 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has raised $32 million in a Series D financing led by ... |
| |
|
More > |
| |
| METABOLEX SHOWS MBX-102/JNJ-39659100 REDUCES INFLAMMATION IN PRECLINICAL MODELS OF DIABETES |
|
| January 17, 2007 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today the results from a preclinical program that showed that MBX-102/JNJ-39659100, the company’s lead insulin sensitizer, potently reduces inflammation in mouse and rat models of diabetes ... |
| |
|
More > |
| |
|
|
|
